Netherton Syndrome (NS) - Thelansis
Epidemiology study reflects Incidence is estimated at 1/200,000 births.
Netherton syndrome (NS) is characterized by ichthyosis linearis circumflexa,
trichorrhexis invaginata, and atopic diathesis. It is also considered a
probable primary immunodeficiency as many patients have shown increased
tendency for infections and abnormal levels of various immunoglobulins. Primary
defect in NS is mutation in SPINK5 (serine protease inhibitor Kazal-type 5)
gene which leads to the defective expression and function of lymphoepithelial
Kazal-type-related inhibitor.
KOLs
insights of NS across 8 MM market from center of Excellence/ Public/
Private hospitals participated in the study. KOL insights covers promising role
of KLK5 and/or KLK7 inhibitors in disease modifying treatment. Insights around
current treatment landscape, epidemiology, clinical characteristics, future
treatment paradigm and Unmet needs.
Competitive landscape of NS
includes country specific approved as well as pipeline therapies, with respect
to terminated and suspended trial.
Approval are being tracked and supplemented with analyst commentary.
Market
Forecasting: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country
specific Forecast Model, Market uptake and patient share uptake, Attribute
Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and
Insights.
1 BPR277 ointment Novartis Pharmaceuticals Novartis Phase 1- No updates
No comments:
Post a Comment